预约演示
更新于：2026-08-03
Metformin Hydrochloride
盐酸二甲双胍
更新于：2026-08-03
概要
基本信息
简介盐酸二甲双胍，商品名为GLUCOPHAGE，用于治疗2型糖尿病。它于1957年在法国首次获批，现在由Bristol Myers Squibb公司生产。GLUCOPHAGE通过激活PRKAB1，帮助改善10岁及以上成人和儿童患者的血糖控制，配合饮食和运动使用。该药物属于双胍类药物，通常用作辅助疗法，帮助管理2型糖尿病患者的血糖水平。 |
药物类型 小分子化药 |
别名 Meiformin Hydrochloride、Metformin hydrochloride (JP17/USP)、Metformin Hydrochlorride + [67] |
靶点 |
作用方式 激活剂 |
作用机制 PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 中国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C4H12ClN5 |
InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N |
CAS号1115-70-4 |
关联
2,951
项与 盐酸二甲双胍 相关的临床试验CTRI/2025/09/094234
A Feasibility Study Comparing a Unani Regimen and Metformin in the management of Type 2 Diabetes Mellitus - NIL
NCT03686657
A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients
NCT07699367
Metformin and Muscle Recovery Following ACL Surgery
100 项与 盐酸二甲双胍 相关的临床结果
登录后查看更多信息
100 项与 盐酸二甲双胍 相关的转化医学
登录后查看更多信息
100 项与 盐酸二甲双胍 相关的专利（医药）
登录后查看更多信息
20,173
项与 盐酸二甲双胍 相关的文献（医药）2026-05-04Expert Opinion On Drug Safety
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases
Article
作者: Koseki, Takenao ; Kondo, Masashi ; Hatano, Masakazu ; Utsunomiya, Ayaka ; Yamada, Shigeki ; Imaizumi, Kazuyoshi
BACKGROUND:
Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).
RESEARCH DESIGN AND METHODS:
We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed.
RESULTS:
We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation.
CONCLUSION:
Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.
2026-05-01ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
A Nasal Hydrogel Combining Metformin and Curcumin for Potential Nose-to-Brain Therapy in Neurodegenerative Disorders
Article
作者: Özyılmaz, Emine Dilek
Neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease remain a significant therapeutic challenge due to the restrictive nature of the blood–brain barrier (BBB) and the limited efficacy of current pharmacological treatments. Intranasal administration has emerged as a promising noninvasive strategy that enables direct drug delivery to the brain by bypassing the BBB. This study aimed to design and optimize a dual-drug nasal hydrogel containing metformin hydrochloride, a hydrophilic AMP-activated protein kinase activator, and curcumin, a lipophilic antioxidant and anti-amyloid agent, and to provide synergistic neuroprotection. The formulation was prepared using carbopol as the gel matrix and characterized in terms of physicochemical stability, drug content uniformity, rheology,
in vitro
release, and excipient compatibility. A Box–Behnken design was used to systematically evaluate the effects of carbopol, glycerin, and curcumin concentrations on critical quality attributes. The optimized hydrogel exhibited acceptable pH, viscosity suitable for nasal administration, and sustained biphasic drug release with a cumulative 6-h release of approximately 85% for metformin and 39% for curcumin according to the Higuchi drug release model (
R2
> 0.98). Collectively, these results highlight the feasibility of an integrative intranasal hydrogel platform to overcome the bioavailability challenges of both agents. The proposed system offers a patient-friendly, noninvasive approach for potential nose-to-brain therapy in neurodegenerative disorders and warrants further preclinical and
in vivo
investigation.
2026-05-01Clinical Pharmacology in Drug Development
Comparative Pharmacokinetics and Bioequivalence Assessment of Metformin/Pioglitazone Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects
Article
作者: Wei, Zijie ; Li, Mengke ; Wang, Xintong ; Liu, Bin ; Chen, Lulu ; Ouyang, Dongsheng ; Li, Chao ; Li, Xiaohui ; Zhou, Ling ; Li, Hongcheng ; Fang, Qing
Abstract:
Metformin/pioglitazone tablets are a fixed‐dose combination of metformin hydrochloride and pioglitazone. In healthy Chinese subjects, this study evaluated the pharmacokinetics and bioequivalence of metformin/pioglitazone (500/15 mg) tablets. We conducted a single‐center, open‐label, randomized, two‐way crossover study in which subjects were randomized in a 1:1 ratio to either the test formulation or the reference formulation, separated by a 10‐day washout period. Blood samples collected at pre‐arranged intervals before and after dosing were analyzed using validated liquid chromatography‐tandem mass spectrometry techniques to determine metformin and pioglitazone plasma concentrations. Finally, subjects completed fasting and fed studies, respectively. In both studies, the 90% confidence intervals for the geometric mean ratios (test/reference) of C
max
, AUC
0–t
, and AUC
0–∞
were within acceptable bioequivalence limits (0.80–1.25), and no serious adverse events were observed. The study demonstrated that the tested and reference formulations of metformin/pioglitazone tablets are bioequivalent and well tolerated under both fasting and fed conditions.
100 项与 盐酸二甲双胍 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 美国 | 2004-04-27 | |
| 2型糖尿病 | 中国 | 1992-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浸润性乳腺癌 | 临床3期 | 美国 | 2024-12-16 | |
| 慢性病 | 临床3期 | 美国 | 2020-07-29 | |
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2019-02-01 | |
| 腹主动脉瘤 | 临床3期 | 奥地利 | 2018-09-26 | |
| 脆性X综合征 | 临床3期 | 美国 | 2018-04-30 | |
| 脆性X综合征 | 临床3期 | 加拿大 | 2018-04-30 | |
| 代谢综合征 | 临床3期 | 美国 | 2017-08-07 | |
| 非典型增生 | 临床3期 | 美国 | 2015-11-23 | |
| 乳腺癌 | 临床3期 | 美国 | 2015-11-23 | |
| 乳腺增生 | 临床3期 | 美国 | 2015-11-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 37 | 顧積築艱獵醖艱繭淵網(艱蓋蓋鏇繭鹹膚製鹽觸) = 構鹽鬱膚鹹艱醖鹹鹽糧 壓顧壓夢餘艱襯艱壓襯 (衊蓋積淵餘鬱選選襯襯, 夢夢鏇構餘構壓鑰範餘 ~ 範築窪繭壓築網繭蓋廠) 更多 | - | 2026-07-20 | |||
N/A | 312 | insulin plus adjunctive therapy (SGLT2i, GLP-1RA, metformin, or DPP4i) | 淵網艱鑰糧選構選鬱鏇(鹽廠夢襯願夢簾簾簾構): OR = 1.73, P-Value = 0.03 更多 | 积极 | 2026-06-20 | ||
insulin monotherapy | |||||||
N/A | 3,770 | 醖餘襯築餘衊網壓廠醖(簾蓋餘積夢糧憲衊簾衊) = 遞淵糧遞鏇醖衊願鑰構 淵鹽襯廠遞夢鹹顧觸壓 (廠遞簾網遞廠積憲選齋 ) 更多 | 积极 | 2026-06-20 | |||
N/A | 2,290 | 鬱襯醖觸鹹鹹簾艱鏇顧(顧糧獵淵夢膚蓋製艱餘) = 鑰衊艱觸齋顧鹹壓鑰願 艱積觸膚餘膚觸襯鏇壓 (齋窪簾鑰鏇願衊餘艱積 ) 更多 | 积极 | 2026-06-20 | |||
鬱襯醖觸鹹鹹簾艱鏇顧(顧糧獵淵夢膚蓋製艱餘) = 衊膚積艱醖鹹網壓鑰艱 艱積觸膚餘膚觸襯鏇壓 (齋窪簾鑰鏇願衊餘艱積 ) | |||||||
N/A | 2,124 | Metformin + ICIs | 蓋築廠構簾壓淵網簾壓(獵窪鏇鹹夢製網築構壓) = 願夢築鬱鏇蓋壓願獵觸 膚製醖構膚構鑰繭選願 (壓願範製築齋築範積糧 ) | 积极 | 2026-05-29 | ||
ICIs | 蓋築廠構簾壓淵網簾壓(獵窪鏇鹹夢製網築構壓) = 顧築選繭廠築壓獵齋淵 膚製醖構膚構鑰繭選願 (壓願範製築齋築範積糧 ) | ||||||
N/A | 1,101 | 夢襯願膚製構餘糧鏇願(築餘廠繭壓築鑰餘艱積) = 壓願壓糧願顧鏇餘遞繭 憲簾廠觸艱醖製憲糧鏇 (選蓋鑰糧製膚構襯繭築 ) | 积极 | 2026-05-29 | |||
- | |||||||
N/A | 6,576 | MET users | 壓觸積鹽膚醖廠獵蓋壓(構簾觸顧範廠製鏇簾蓋) = 顧選艱製夢壓簾遞獵蓋 願夢鹹醖鑰鏇簾糧鹹憲 (願積製選選觸鹹窪願獵 ) | 积极 | 2026-05-12 | ||
Non-users | 壓觸積鹽膚醖廠獵蓋壓(構簾觸顧範廠製鏇簾蓋) = 餘襯鏇製夢齋鏇蓋膚製 願夢鹹醖鑰鏇簾糧鹹憲 (願積製選選觸鹹窪願獵 ) | ||||||
临床2期 | 21 | (Arm 1: Metformin Before Pembrolizumab) | 衊觸襯選獵願壓蓋築夢 = 糧蓋築壓獵製顧壓鏇獵 製構窪獵鹹糧鏇糧淵繭 (鏇簾淵窪蓋壓願鹹鹽鬱, 襯網遞餘餘齋夢繭窪構 ~ 壓顧鑰艱廠淵壓製觸糧) 更多 | - | 2026-05-08 | ||
(Arm 2: Metformin After Pembrolizumab) | 衊觸襯選獵願壓蓋築夢 = 窪獵願築簾範餘夢餘襯 製構窪獵鹹糧鏇糧淵繭 (鏇簾淵窪蓋壓願鹹鹽鬱, 鏇鏇願襯齋鑰選獵醖襯 ~ 淵艱築鹽範膚夢鹹觸齋) 更多 | ||||||
临床2期 | 29 | 積醖鏇衊衊糧餘觸餘顧(遞積餘窪觸築遞壓鬱範) = 鑰襯製鏇構鬱淵餘鬱簾 醖鑰蓋鑰範鏇選網襯鬱 (衊鬱願壓糧鑰廠鑰襯壓, 夢築蓋糧製衊膚願餘餘 ~ 憲廠鹹鹽鏇遞築鑰網衊) 更多 | - | 2026-04-22 | |||
临床2期 | 111 | Chemotherapy+metformin hydrochloride (Metformin Plus Chemotherapy) | 繭窪餘鹹範鹽願簾襯繭(壓願糧壓夢築鏇餘鬱鹹) = 繭夢壓憲艱淵艱壓鬱鏇 艱廠艱鹹網衊鹹觸廠鬱 (醖觸簾鹽鏇繭餘觸積齋, 淵淵選獵鹽網襯鹽醖膚 ~ 鏇範憲製顧構獵鹹夢簾) 更多 | - | 2026-03-27 | ||
placebo (Placebo Plus Chemotherapy) | 繭窪餘鹹範鹽願簾襯繭(壓願糧壓夢築鏇餘鬱鹹) = 積築鹹窪築襯積醖窪襯 艱廠艱鹹網衊鹹觸廠鬱 (醖觸簾鹽鏇繭餘觸積齋, 衊積膚選鹹遞觸繭築憲 ~ 獵觸壓顧鬱製鏇艱築憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用